Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Safe Use workshop set

This article was originally published in The Tan Sheet

Executive Summary

FDA officials discuss the status of Safe Use Initiative activities and future projects at a public workshop in November. According to the agency's website, FDA will gather input and perspectives for directions toward the development of "collaborative, cross-sector safe medication use activities with healthcare stakeholders." FDA scheduled the meeting for Nov. 16, 8:30 a.m. to 4:45 p.m. EST, and Nov. 17, 8:30 a.m. to 12 p.m., in Silver Spring, Md. FDA launched the initiative in 2008 to reduce the likelihood of preventable injury and death caused by medical errors, unintentional exposure to drugs, misuse, abuse or attempts at self-harm (1"The Tan Sheet" May 10, 2010)

You may also be interested in...



Acetaminophen Awareness Coalition Prepares To Launch Education Campaign

Consumer health advocates, trade groups and FDA representatives are working together to raise awareness of safe acetaminophen use and to address an advisory committee's concerns about the painkiller.

Drug Industry Avoids FDA's "Blunt Tools" With Safe Use Initiative Progress

Efforts by firms and other pharmaceutical industry stakeholders to drive FDA's Safe Use Initiative agenda lower the likelihood of the agency intervening with enforcement action, according to Principal Deputy Commissioner Josh Sharfstein

Evusheld: UK Urged To Use RWD To Give Clinically Vulnerable Early Access To COVID-19 Treatment

A full appraisal by the UK cost watchdog is not the only way to gauge the safety and effectiveness of Evusheld, argues the independent Drug Safety Research Unit in response to the government’s decision not to buy the licensed COVID-19 drug because of insufficient data on protection. 

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS104544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel